W. S. Singleton
About
W. S. Singleton is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, W. S. Singleton has authored 56 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 10 papers in Surgery and 10 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in W. S. Singleton's work include Lipoproteins and Cardiovascular Health (8 papers), Analytical Chemistry and Chromatography (7 papers) and Lipid metabolism and disorders (7 papers). W. S. Singleton is often cited by papers focused on Lipoproteins and Cardiovascular Health (8 papers), Analytical Chemistry and Chromatography (7 papers) and Lipid metabolism and disorders (7 papers). W. S. Singleton collaborates with scholars based in United States, Canada and United Kingdom. W. S. Singleton's co-authors include M. L. Brown, John White, M. S. Gray, Richard S. Geary, Rosanne M. Crooke, Brenda F. Baker, Mark J. Graham, Steven G. Hughes, Joseph L. Witztum and Veronica J. Alexander and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
W. S. Singleton
56 papers receiving 3.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| W. S. Singleton United States | 18 | 1.4k | 1.2k | 1.2k | 1000 | 485 | 56 | 3.9k | ||
| Louis C. Smith United States | 36 | 2.4k 1.6× | 698 0.6× | 1.2k 1.0× | 965 1.0× | 504 1.0× | 96 | 5.2k | ||
| C.M. van Gent Netherlands | 25 | 1.1k 0.8× | 333 0.3× | 769 0.7× | 514 0.5× | 201 0.4× | 62 | 3.3k | ||
| Jan‐Olof Jeppsson Sweden | 33 | 1.7k 1.2× | 317 0.3× | 523 0.5× | 1.5k 1.5× | 588 1.2× | 74 | 5.0k | ||
| Joel D. Morrisett United States | 47 | 3.3k 2.3× | 1.3k 1.1× | 2.9k 2.5× | 1.7k 1.7× | 1.3k 2.8× | 167 | 8.3k | ||
| James T. Dodge United States | 16 | 2.5k 1.8× | 1.9k 1.6× | 1.9k 1.6× | 293 0.3× | 85 0.2× | 21 | 7.3k | ||
| G.M. Anantharamaiah United States | 34 | 1.8k 1.3× | 531 0.4× | 2.1k 1.8× | 1.6k 1.6× | 741 1.5× | 70 | 4.9k | ||
| Giuseppe Palumbo Italy | 33 | 1.3k 0.9× | 310 0.3× | 497 0.4× | 453 0.5× | 308 0.6× | 103 | 3.8k | ||
| Andrew D. Watson United States | 35 | 2.5k 1.7× | 647 0.5× | 1.6k 1.4× | 821 0.8× | 573 1.2× | 64 | 7.3k | ||
| Giovanni Colonna Italy | 37 | 2.1k 1.5× | 1.3k 1.1× | 1.1k 1.0× | 139 0.1× | 336 0.7× | 182 | 5.5k | ||
| Amir Ravandi Canada | 36 | 1.2k 0.8× | 713 0.6× | 999 0.9× | 442 0.4× | 318 0.7× | 145 | 3.8k |
Countries citing papers authored by W. S. Singleton
Since
Specialization
Citations
This map shows the geographic impact of W. S. Singleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. S. Singleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. S. Singleton more than expected).
Fields of papers citing papers by W. S. Singleton
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by W. S. Singleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. S. Singleton. The network helps show where W. S. Singleton may publish in the future.
Co-authorship network of co-authors of W. S. Singleton
This figure shows the co-authorship network connecting the top 25 collaborators of W. S. Singleton. A scholar is included among the top collaborators of W. S. Singleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. S. Singleton. W. S. Singleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gaudet, Daniel, Ewa Karwatowska‐Prokopczuk, Seth J. Baum, et al.. (2020). Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal. 41(40). 3936–3945.
2.
Tsimikas, Sotirios, Nicholas J. Viney, Steven G. Hughes, et al.. (2015). Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. The Lancet. 386(10002). 1472–1483.
3.
Yu, Rosie Z., Rudy Gunawan, Zhaoyang Li, et al.. (2015). No effect on QT intervals of mipomersen, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects. European Journal of Clinical Pharmacology. 72(3). 267–275.
4.
Gaudet, Daniel, Veronica J. Alexander, Brenda F. Baker, et al.. (2015). Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. New England Journal of Medicine. 373(5). 438–447.
5.
Warren, Marshelle, Steven G. Hughes, W. S. Singleton, Mason Yamashita, & Mark C. Genovese. (2015). Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis. Arthritis Research & Therapy. 17(1). 80–80.
6.
Gaudet, Daniel, Wei Cheng, JoAnn Flaim, et al.. (2014). AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III SIGNIFICANTLY DECREASES APOLIPOPROTEIN C-III, TRIGLYCERIDES, VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER, AND INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER IN HYPERTRIGLYCERIDEMIC PATIENTS ON A FIBRATE. Journal of the American College of Cardiology. 63(12). A1453–A1453.
7.
Gaudet, Daniel, Diane Brisson, Karine Tremblay, et al.. (2014). Targeting APOC3 in the Familial Chylomicronemia Syndrome. New England Journal of Medicine. 371(23). 2200–2206.
8.
Gaudet, Daniel, Veronica J. Alexander, Diane Brisson, et al.. (2014). An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency. Journal of clinical lipidology. 8(3). 353–354.
9.
Viney, N., Mark Graham, Rosanne M. Crooke, Steve Hughes, & W. S. Singleton. (2013). Abstract 14196: Evaluation of Isis Apo(a)Rx, an Antisense Inhibitor to Apolipoprotein(a), in Healthy Volunteers. Circulation. 128.
10.
Viney, Nicholas J., et al.. (2012). AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III LOWERS FASTING PLASMA APOLIPOPROTEIN C-III AND TRIGLYCERIDE CONCENTRATIONS IN HEALTHY VOLUNTEERS. Journal of the American College of Cardiology. 59(13). E1685–E1685.
11.
Jones, Nicholas, Melissa A. Pegues, Mark A. McCrory, et al.. (2012). A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans. Molecular Therapy — Nucleic Acids. 1. e52–e52.
12.
Molina, Carlos A., Andrew D. Barreto, Georgios Tsivgoulis, et al.. (2009). Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Annals of Neurology. 66(1). 28–38.
13.
Singleton, W. S., et al.. (1989). Efficacy and safety of Minipress XL, a new once-a-day formulation of prazosin. The American Journal of Medicine. 87(2). S45–S52.
14.
Chung, Menger, Donald P. Reitberg, Michael Gaffney, & W. S. Singleton. (1987). Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. The American Journal of Medicine. 83(6). 10–14.
15.
Singleton, W. S., et al.. (1982). Postjunctional Selectivity of α-Blockade with Prazosin, Trimazosin, and UK-33,274 in Man. Journal of Cardiovascular Pharmacology. 4. S145–S151.
16.
Thadani, Udho, Christopher Davidson, W. S. Singleton, & Stanley H. Taylor. (1980). Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. The American Journal of Medicine. 68(2). 243–250.
17.
Singleton, W. S., et al.. (1960). Effects of prolonged intravenous administration of fat emulsions on serum proteins of dogs.. Metabolism. 9. 956–965.
18.
Benerito, Ruth R., et al.. (1957). Quantitative Determination of Serum Proteins by Paper Electrophoresis...Rapid Dyeing Method. Analytical Chemistry. 29(12). 1816–1820.
19.
Singleton, W. S. & T. L. Ward. (1953). The effect of positional and geometrical isomerism on the dilatometric properties of some octadecenoic acids. Journal of the American Oil Chemists Society. 30(12). 592–594.
20.
Singleton, W. S., et al.. (1951). Dilatometric investigations of fats. V. volume changes associated with the polymorphism and melting of monostearin. Journal of the American Oil Chemists Society. 28(8). 342–343.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Louis C. Smith Breakdown of academic impact, for papers by C.M. van Gent Breakdown of academic impact, for papers by Jan‐Olof Jeppsson Breakdown of academic impact, for papers by Joel D. Morrisett Breakdown of academic impact, for papers by James T. Dodge Breakdown of academic impact, for papers by G.M. Anantharamaiah Breakdown of academic impact, for papers by Giuseppe Palumbo Breakdown of academic impact, for papers by Andrew D. Watson Breakdown of academic impact, for papers by Giovanni Colonna Breakdown of academic impact, for papers by Amir Ravandi